1.1—Programmable cGAMP Platform for Next-Gen Immunotherapy and Diagnostics

This platform harnesses a novel microbial enzyme to efficiently produce 2′,3′-cGAMP—a powerful activator of the STING pathway—with broad applications in cancer immunotherapy, infectious disease and vaccine development. Paired with a chimeric biosensor that enables highly specific, real-time detection of cGAMP in complex biological samples, the system supports both therapeutic and diagnostic innovation. Together, these technologies provide end-to-end control over cGAMP biology—from programmable production to precision monitoring—empowering entrepreneurs to build next-generation immunotherapies, diagnostics or high-throughput screening tools.

Inventor: Aaron Whiteley (CU Boulder Biochemistry)

Potential Applications: Health and Wellness, Biotech, Diagnostics, Therapeutics